MiR-185 plays an anti-hypertrophic role in the heart via multiple targets in the calcium-signaling pathways

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Kim, Jin Ock ^a   Song, Dong Woo ^a   Kwon, Eun Jeong ^a   Hong, Seong Eui ^a   Song, Hong Ki ^a   Min, Choon Kee ^a   Kim, Do Han ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CAMK2D PROTEIN; LUCIFERASE; MICRORNA; MICRORNA 185; NCX1 PROTEIN; NFATC3 PROTEIN; PHOSPHOLAMBAN; PROTEIN; RNA; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; UNTRANSLATED RNA; CALCIUM; MIRN185 MICRORNA, MOUSE; MIRN185 MICRORNA, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; GENETIC MANIPULATION; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HYPERTROPHIC CARDIOMYOPATHY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; RAT; RNA TRANSLATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CARDIAC MUSCLE; CARDIOMEGALY; GENETICS; MALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

RATTUS;

ANIMALS; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOMEGALY; MALE; MICE; MICRORNAS; MYOCARDIUM; NFATC TRANSCRIPTION FACTORS; RATS; SIGNAL TRANSDUCTION;

EID: 84929470100     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122509     Document Type: Article

References (69)

1. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003;65:45-79. PMID: 12524460
2. Gladka MM, da Costa Martins Pa, De Windt LJ. Small changes can make a big difference.microRNA regulation of cardiac hypertrophy. J Mol Cell Cardiol. 2012;52:74-82. doi: 10.1016/j.yjmcc.2011.09. 015 PMID: 21971075
3. Ding S-L, Zhou L-Y, Li P-F. MicroRNAs in cardiac hypertrophy: angels or devils. Wiley Interdiscip Rev RNA. 2011;2:124-134. doi: 10.1002/wrna.61 PMID: 21956973
4. Leite-Moreira AM, Lourenco AP, Falcao-Pires I, Leite-Moreira AF. Pivotal role of microRNAs in cardiac physiology and heart failure. Drug Discov Today. 2013;18:1243-1249. doi: 10.1016/j.drudis.2013.07. 025 PMID: 23954179
5. Oka T, Komuro I. Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J. 2008;72 Suppl A:A13-A16. PMID: 18772527
6. Barry SP, Davidson SM, Townsend PA. Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol. 2008;40:2023-2039. doi: 10.1016/j.biocel.2008.02.020 PMID: 18407781
7. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-233. doi: 10. 1016/j.cell.2009.01.002 PMID: 19167326
8. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469:336-342. doi: 10.1038/nature09783 PMID: 21248840
9. Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation. 2013;127:2097-2106. doi: 10.1161/CIRCULATIONAHA.112.000882 PMID: 23625957
10. Castaldi A, Zaglia T, Di Mauro V, Carullo P, Viggiani G, Borile G, et al. MiR-133 Modulates the β1Adrenergic Receptor Transduction Cascade. Circ Res. 2014;115:273-283. doi: 10.1161/CIRCRESAHA. 115.303252 PMID: 24807785
11. Van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006;103:18255-18260. PMID: 17108080
12. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol. 2007;170:1831-1840. PMID: 17525252
13. Cha H, Kim JM, Oh JG, Jeong MH, Park CS, Park J, et al. PICOT is a critical regulator of cardiac hypertrophy and cardiomyocyte contractility. J Mol Cell Cardiol. 2008;45:796-803. doi: 10.1016/j.yjmcc. 2008.09.124 PMID: 18929570
14. Song DW, Ryu JY, Kim JO, Kwon EJ, Kim DH. The miR-19a/b family positively regulates cardiomyocyte hypertrophy by targeting atrogin-1 and MuRF-1. Biochem J. 2014;457:151-162. doi: 10.1042/BJ20130833 PMID: 24117217
15. Wang C, Wang S, Zhao P, Wang X, Wang J, Wang Y, et al. MiR-221 Promotes Cardiac Hypertrophy In vitro Through the Modulation of p27 Expression. J Cell Biochem. 2012;113:2040-2046. doi: 10.1002/jcb.24075 PMID: 22275134
16. Da Costa Martins PA, Salic K, Gladka MM, Armand A-S, Leptidis S, El Azzouzi H, et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol. 2010;12:1220-1227. doi: 10.1038/ncb2126 PMID: 21102440
17. Song X-W, Li Q, Lin L, Wang X-C, Li D-F, Wang G-K, et al. MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. J Cell Physiol. 2010;225:437-443. doi: 10.1002/jcp. 22217 PMID: 20458739
18. Wang J, Song Y, Zhang Y, Xiao H, Sun Q, Hou N, et al. Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res. 2012;22:516-527. doi: 10.1038/cr. 2011.132 PMID: 21844895
19. Bernardo BC, Gao X-M, Winbanks CE, Boey E J H, Tham YK, Kiriazis H, et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A. 2012;109:17615-17620. doi: 10.1073/pnas.1206432109 PMID: 23047694
20. Da Costa Martins Pa, De Windt LJ. MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res. 2012;93:563-572. doi: 10.1093/cvr/cvs013 PMID: 22266752
21. Yaosheng Wang, Xiaoshu Cheng, Kui Hong, Yanging Wu, Wu Qinghua SH. MicroRNA-223 prevents cardiomyocyte hypertrophy by targeting cardiac troponin-I-interacting kinase. Heart. 2011;97:A49-A51.
22. Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol. 2009;29:2193-2204. doi: 10.1128/MCB.01222-08 PMID: 19188439
23. Li Q, Xie J, Li R, Shi J, Sun J, Gu R, et al. Overexpression of microRNA-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction. J Cell Mol Med. 2014;18:919-928. doi: 10.1111/jcmm.12242 PMID: 24628978
24. Small EM, O'Rourke JR, Moresi V, Sutherland LB, McAnally J, Gerard RD, et al. Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci U S A. 2010;107:4218-4223. doi: 10.1073/pnas.1000300107 PMID: 20142475
25. Alexander M, Casar J. MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms. J Clin Invest. 2014;124:2651-2667. doi: 10.1172/JCI73579 PMID: 24789910
26. Belkaya S, Murray SE, Eitson JL, de la Morena MT, Forman JA, van Oers NS. Transgenic expression of microRNA-185 causes a developmental arrest of T cells by targeting multiple genes including Mzb1. J Biol Chem. 2013;288:30752-30762. doi: 10.1074/jbc. M113.503532 PMID: 24014023
27. Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51:468-473. doi: 10.1016/j.yjmcc.2011.01.012 PMID: 21276796
28. Hagemann D, Kuschel M, Kuramochi T, Zhu W, Cheng H, Xiao R-P. Frequency-encoding Thr17 phospholamban phosphorylation is independent of Ser16 phosphorylation in cardiac myocytes. J Biol Chem. 2000;275:22532-22536. PMID: 10825152
29. 2+ Exchange: Molecular and Pharmacological Aspects. Circ Res. 2001;88:864-876. PMID: 11348995
30. 2+ exchangers. J Mol Cell Cardiol. 2006;41:807-815. PMID: 16859700
31. 2+ exchanger confers protection against ischemia/reperfusion injury. Circ Res. 2005;97:916-921. PMID: 16179590
32. Gray RP, McIntyre H, Sheridan DS, Fry CH. Intracellular sodium and contractile function in hypertrophied human and guinea-pig myocardium. Pflögers Arch. 2001;442:117-123.
33. + concentration and altered Na/K pump activity in hypertrophied canine ventricular cells. Cardiovasc Res. 2003;57:1035-1043. PMID: 12650881
34. Lu Y-M, Huang J, Shioda N, Fukunaga K, Shirasaki Y, Li XM, et al. CaMKIIOB mediates aberrant NCX1 expression and the imbalance of NCX1/SERCA in transverse aortic constriction-induced failing heart. PLoS One. 2011;6:e24724. doi: 10.1371/journal.pone.0024724 PMID: 21931829
35. 2+ exchanger remodeling in pressure overload cardiac hypertrophy. J Biol Chem. 2001;276:17706-17711. PMID: 11279089
36. 2+ exchanger in end-stage human heart failure. Circ Res. 1994;75:443-453. PMID: 8062418
37. Roos K, Jordan M, Fishbein M, Ritter M, Friedlander M, Chang HC, et al. Hypertrophy and heart failure in mice overexpressing the cardiac sodium-calcium exchanger. Card Fail. 2007;13:318-329. PMID: 17517353
38. 2+ exchanger inhibitors SEA0400 and KB-R7943. Am J Physiol Heart Circ Physiol. 2003;284:H903-H910. PMID: 12446284
39. 2+ exchanger, during ischemia and reperfusion in guinea-pig myocardium. Life Sci. 2005;77:312-324. PMID: 15878358
40. Tritsch E, Mallat Y, Lefebvre F, Diguet N, Escoubet B, Blanc J, et al. An SRF/miR-1 axis regulates NCX1 and annexin A5 protein levels in the normal and failing heart. Cardiovasc Res. 2013;98:372-380. doi: 10.1093/cvr/cvt042 PMID: 23436819
41. Karakikes I, Chaanine AH, Kang S, Mukete BN, Jeong D, Zhang S, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc. 2013;2:e000078. doi: 10.1161/JAHA.113.000078 PMID: 23612897
42. 2+ overload and cell death. J Clin Invest. 2012;122:1222-1232. doi: 10.1172/JCI59327 PMID: 22426211
43. 2+ exchanger, attenuates reperfusion injury in the in vitro and in vivo cerebral ischemic models. J Pharmacol Exp Ther. 2001;298:249-256. PMID: 11408549
44. Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res. 2004;63:467-475. PMID: 15276472
45. Shimoyama M, Hayashi D, Takimoto E, Zou Y, Oka T, Uozumi H, et al. Calcineurin Plays a Critical Role in Pressure Overload-Induced Cardiac Hypertrophy. Circulation. 1999;100:2449-2454. PMID: 10595959
46. Saito T. Roles of calcineurin and calcium/calmodulin-dependent protein kinase II in pressure overloadinduced cardiac hypertrophy. J Mol Cell Cardiol. 2003;35:1153-1160. PMID: 12967638
47. Wilkins BJ, Windt LJ De, Bueno OF, Braz JC, Glascock BJ, Kimball TF, et al. Targeted disruption of NFATc3, but Not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol. 2002;22:7603-7613. PMID: 12370307
48. 2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest. 2009;119:1230-1240. doi: 10.1172/JCI38022 PMID: 19381018
49. Anderson ME, Heller J, Bers DM. Journal of Molecular and Cellular Cardiology CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51:468-473. doi: 10.1016/j.yjmcc.2011.01.012 PMID: 21276796
50. 2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem. 2002;277:1261-1267. PMID: 11694533
51. Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J Jr, Bers DM, et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res. 2003;92:912-919. PMID: 12676814
52. Backs J, Backs T, Neef S, Kreusser MM, Lehmann LH, Patrick DM, et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A. 2009;106:2342-2347. doi: 10.1073/pnas.0813013106 PMID: 19179290
53. Backs J, Song K, Bezprozvannaya S, Chang S, Olson EN. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest. 2006;116:1853-1864. PMID: 16767219
54. Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell. 2010;40:762-773. doi: 10.1016/j.molcel.2010.11.038 PMID: 21145484
55. Elia L, Contu R, Quintavalle M, Varrone F, Chimenti C, Russo MA, et al. Reciprocal regulation of micro-RNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation. 2009;120:2377-2385. doi: 10.1161/CIRCULATIONAHA.109.879429 PMID: 19933931
56. Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, et al. MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol. 2012;84:320-330. doi: 10.1016/j.bcp. 2012.04.017 PMID: 22580051
57. Knezevic I, Patel A, Sundaresan NR, Gupta MP, Solaro RJ, Nagalingam RS, et al. A novel cardiomyocyteenriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival. J Biol Chem. 2012;287:12913-12926. doi: 10.1074/jbc. M111. 331751 PMID: 22367207
58. Lerman G, Avivi C, Mardoukh C, Barzilai A, Tessone A, Gradus B, et al. MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS One. 2011;6:e20916. doi: 10.1371/journal.pone.0020916 PMID: 21687694
59. Luo M, Shen D, Zhou X, Chen X, Wang W. MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery. 2013;153:836-847. doi: 10.1016/j.surg.2012.12.004 PMID: 23453369
60. Wang J, Wang Y, Wang Y, Ma Y, Lan Y, Yang X. Transforming growth factor β-regulated microRNA-29a promotes angiogenesis through targeting the phosphatase and tensin homolog in endothelium. J Biol Chem. 2013;288:10418-10426. doi: 10.1074/jbc. M112.444463 PMID: 23426367
61. Zhang L, Deng T, Li X, Liu H, Zhou H, Ma J, et al. microRNA-141 is involved in a nasopharyngeal carcinomarelated genes network. Carcinogenesis. 2010;31:559-566. doi: 10.1093/carcin/bgp335 PMID: 20053927
62. Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet. 2007;370:1443-1452. PMID: 17950858
63. Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci. 2010;11:402-416. doi: 10.1038/nrn2841 PMID: 20485365
64. De la Morena MT, Eitson JL, Dozmorov IM, Belkaya S, Hoover AR, Anguiano E, et al. Signature Micro-RNA expression patterns identified in humans with 22q11.2 deletion/DiGeorge syndrome. Clin Immunol. 2013;147:11-22. doi: 10.1016/j.clim.2013.01.011 PMID: 23454892
65. Liu M, Lang N, Chen X, Tang Q, Liu S, Huang J, et al. miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells. Cancer Lett. 2011;301:151-160. doi: 10.1016/j.canlet.2010.11.009 PMID: 21186079
66. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res. 2006;98:730-742. PMID: 16574914
67. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13:613-618. PMID: 17468766
68. Zhang Z, Liu X, Feng B, Liu N, Wu Q, Han Y, et al. STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer. Oncogene. In press.
69. 2+ entry is required for pathological cardiac hypertrophy. J Mol Cell Cardiol. 2012;52:136-147. doi: 10.1016/j.yjmcc.2011.11.003 PMID: 22108056